Resources
About Us
Home Report
Store
Multiplex Assays Market
Multiplex Assays Market Size, Share, Forecast, & Trends Analysis by Type (Protein [Bead, Planar], Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis (Oncology, Infectious) Product, End User - Global Forecast to 2031
Report ID:MRHC - 104915 Pages: 262 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursMultiplex Assays Market Size & Forecast
The Multiplex Assays Market is expected to reach $6.80 billion by 2031 at a CAGR of 8.9% from 2024 to 2031. Multiplex assays are a form of immunoassay that measures several analytes at once. These assays are derived from the conventional ELISA technology, which generates numerous signal measurements instead of only one, as in ELISA. Multiplex assays use microspheres coated with several antibodies that come in various colors. It uses flow cytometry to separate various colored beads by their diverse degrees of fluorescence, the findings of which are read following incubation.
The growth of this market is attributed to several factors: the advantages of multiplex assays over singleplex assays, the use of multiplexing in companion diagnostics, the increasing prevalence of chronic and infectious diseases, rising use of multiplex assays in drug discovery, and rising awareness about the importance of early disease diagnosis. However, the high costs of multiplex assay equipment restrain the growth of this market.
The growing need for high-throughput and automated laboratory systems and the increasing focus on personalized medicine are expected to generate growth opportunities for the players operating in this market. However, the shortage of skilled professionals and the risk of cross-reactivity are major challenges to market growth.
Multiplex Assays Market Growth Drivers
Advantages of Multiplex Assays over Singleplex Assays
In recent years, scientists and researchers have increasingly adopted multiplex assays due to their advantages over singleplex assays. Multiplex assays generate more reproducible and robust results compared to singleplex assays. These assays are more reliable than singleplex assays, can simultaneously analyze multiple analytes, reduce the chances of human error, and offer more accurate results. Additionally, multiplex assays use similar experimental criteria for all analytes, making experiment results more easily comparable.
The main advantage multiplex assays offer over singleplex assays is their lower sample requirement. The multiplex approach uses lower quantities of samples, reducing associated costs and providing all the required data points from a single reaction. Although singleplex assays are simpler to perform than multiplex assays, the results are more accurate and informative, which drives the preference for multiplex assays among end users.
Click here to: Get Free Sample Pages of this Report
Use of Multiplex Assays in Drug Discovery
Pharmaceutical & biotechnology companies allocate significant resources for drug discovery & development. The increasing prevalence of chronic diseases is increasing the need for the development of novel therapies, thus focus on drug discovery is increasing. Multiplex assays have become increasingly important in maintaining precision and accuracy in drug research and development and reducing the time required for research purposes. Multiplex assays are used in biomarker discovery and validation. Identifying and characterizing biomarkers can streamline the drug candidate selection process, thus reducing the number of failures in clinical trials and enabling the discovery of more effective therapeutics hence adopted.
The funding for drug discovery is also increasing, which is driving the demand for multiplex assays. For instance, in March 2023, the Government of Canada provided a fund of USD 59 million to the Canadian Critical Drug Initiative to boost drug research, commercialization, and manufacturing in the Alberta province.
Multiplex Assays Market Trends
Integration of Artificial Intelligence
Disease diagnosis often requires identifying candidate pathogenic variants and determining the correspondence between the diseased individual’s phenotype and pathogenic variant. The integration of AI algorithms into multiplex assays can significantly enhance phenotype-genotype mapping. In molecular diagnostics, automated systems are also used to accurately spot target genes and design oligonucleotide primers, which are important in developing multiplex assays. By compiling data from assay development, diagnostics companies can artificially find the most efficient genetic target for developing a specific multiplexed assay.
Using AI, companies can speed up the development of diagnostic tests by automating the assay designing phase. AI is also incorporated in multiplex assays for drug discovery and design. AI plays a crucial role in drug repurposing, drug target identification & validation, multi-target drug discovery, and biomarker identification. For instance, Seegene, Inc. (South Korea) developed the first multiplex assay with an AI-based system. AI developed the entire assay in just four days. The assay is used to simultaneously detect eight different DNA targets for sexually transmitted infections and meningitis.
Development of Smartphone-based Diagnostic Testing Platforms
The demand for high-quality medical services is rising continuously. Smartphone-based platforms find applications in tele-imaging, food technology, and education. Smartphone-based detection is versatile and has a wide range of medical applications. Diagnostic multiplex assays play an important role in simultaneously detecting multiple pathogens. With high diagnosis costs and the limited availability of benchtop readers in remote/resourceless areas, the demand for smartphone-based multiplex diagnostics is rising continuously. These smartphone-based end-to-end platforms are complemented with deep learning methods to further increase device efficiency. These smartphone-based detection methods provide automated detection and analysis of the results and support human expertise. The transactions involved in patient data handling are secured via blockchain technology. For instance, Luminostics, Inc. (U.S.) received the FDA’s Emergency Use Authorization (EUA) for its Clip COVID Rapid Antigen Test, a rapid (results generated in 15 minutes), smartphone-connected antigen immunoassay that uses glow-in-the-dark nanomaterials to detect and differentiate SARS-CoV-2 and influenza A/B.
Multiplex Assays Market Opportunities
Increasing Focus on Personalized Medicine
Personalized/precision medicine uses an individual’s genomic information to offer targeted treatment. Multiplex assays can simultaneously detect multiple biomarkers, driving their utilization in precision medicine. Multiplex assay approaches are used to identify changes in gene expression, genetic variations, or epigenetic modifications associated with a particular disease or condition; thus, these assays are useful in developing personalized medicines.
Additionally, cell-based multiplexing is an important aspect of personalized medicine as it creates a cell or tissue-specific spatial context for extending, interpreting, and understanding the information captured from multiple biomarkers, which can be important in guiding treatment decisions in personalized medicine.
According to an article published in the MDPI journal in 2020, multiplex immunoassays provide an overall understanding of the disease and pathways involved in Rheumatoid Arthritis (RA) and simultaneously analyze multiple proteins that can yield biomarker signatures of RA subtypes to enable patients to benefit from personalized medicine.
Multiplex Assays Market Analysis: Key Findings
By Type: In 2024, the Protein Multiplex Assays Segment to Dominate the Multiplex Assays Market
Based on type, the multiplex assays market is segmented into protein multiplex assays, nucleic acid multiplex assays, and cell-based multiplex assays. In 2024, the protein multiplex assays segment is expected to account for the largest share of 53.3% of the multiplex assays market. Protein multiplex assays are segmented into bead-based assays and planar assays. In 2024, the bead-based assays segment is expected to account for the largest share of the protein multiplex assays market. Multiplex bead-based assays have become essential tools for diagnosing various diseases. These assays are used for testing allergies, cancer markers, cytokines, cardiac markers, autoimmune diseases, and endocrine diseases. Their increasing application areas in clinical diagnostics and R&D are driving the market's growth. Also, bead-based assays require a limited sample volume and less time, thus making it a preferable technique for studies or experiments of many factors, such as pituitary hormones and cytokines, thereby contributing to the largest share of the segment.
By Product: In 2024, the Consumables Segment to Dominate the Multiplex Assays Market
Based on product, the multiplex assays market is segmented into consumables, instruments, and software & services. In 2024, the consumables segment is expected to account for the largest share of the multiplex assays market. Diagnostic kits are designed to provide highly accurate results with minimal risk of user error. They are pre-packaged with all the necessary materials and reagents, ensuring that the correct amounts are used while reducing the risk of contamination. Assay kits are used in various applications, including COVID-19 diagnosis, infectious disease testing, oncology, cardiovascular, and other applications, contributing to the largest share of the segment.
By Technology: In 2024, the Flow Cytometry Segment to Dominate the Multiplex Assays Market
Based on technology, the multiplex assays market is segmented into flow cytometry, multiplex real-time PCR, multiplex immunoassay, sequencing, and other technologies. In 2024, the flow cytometry segment is expected to account for the largest share of 40.0% of the multiplex assays market. Flow cytometry technology is preferred over other technologies due to its rapid, high-throughput, and sensitive results. Its reproducible detection capabilities make it ideal for various biomedical applications requiring multiplex protein or nucleic acid analyte detection. Additionally, the high penetration of flow cytometry in both research & development and clinical diagnosis contributes to the largest share of the segment.
By Application: In 2024, the Research & Development Segment to Dominate the Multiplex Assays Market
Based on application, the multiplex assays market is segmented into research & development and clinical diagnosis applications. In 2024, the research & development segment is expected to account for the largest share of the multiplex assays market. Multiplex assays are increasingly used in the research & development of personalized medicines and research programs for understanding disease mechanisms. Furthermore, increasing pharmaceutical research & development spending, rising new molecular entity approvals, and the launch of multiplex assay panels for research applications by the key players contribute to the largest share of the segment.
By End User: In 2024, the Pharmaceutical & Biotechnology Companies Segment to Dominate the Multiplex Assays Market
Based on end user, the multiplex assays market is segmented into pharmaceutical & biotechnology companies, diagnostic laboratories, hospitals, and other end users. In 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the market. The rising number of research laboratories, increasing investment in R&D, and rising funding for research laboratories support the largest share of the market. The funding for research laboratories is increasing due to the increasing demand for new drugs and therapies and advancements in laboratory equipment. For instance, in 2021, the U.S. Federal Government invested USD 179.5 billion in R&D. (Source: U.S. Government Accountability Office). Additionally, pharmaceutical companies are increasingly partnering with CROs for product development. The expansion of CROs to meet the growing demand for new product development also supports the market's largest share.
Geographical Analysis
In 2024, North America to Dominate the Market
In 2024, North America is expected to account for the largest share of 39.2% of the multiplex assays market. The large market share of this region is attributed to the high prevalence of chronic and infectious diseases, awareness regarding early disease diagnosis, high adoption of advanced diagnostic products, and increasing funding activities. According to the U.S. Department of Health & Human Services, in 2022, the National Institute of Health (NIH) allocated USD 45 billion for biomedical research. Moreover, the government partnership with key players for the development of multiplex assay, rising prevalence of cancer, strong academic research, and the presence of key players are contributing to the largest share of the market.
Asia-Pacific is expected to grow at the highest CAGR of 10.8% during the forecast period. The growth of the multiplex assays market in Asia-Pacific is attributed to the rising research funding in the healthcare and pharmaceutical industry, the rising number of research laboratories, the advancing research framework, and the growing number of diagnostic laboratories in countries such as China, India, Japan, South Korea, and others. For instance, in 2022, the R&D spending of BeiGene Ltd. (China), one of the major pharmaceutical companies, increased by 12.4% from 2021. The increasing use of multiplex immunoassay in precision medicine and government initiatives for precision medicine is also driving the market growth.
Multiplex Assays Market: Key Companies
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years . The key players operating in the multiplex assays market are Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Seegene, Inc. (South Korea), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Illumina, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Quanterix Corporation (U.S.), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany).
Multiplex Assay Market Overview: Latest Developments from Key Industry Players
-
In April 2023, Seegene, Inc. (South Korea) partnered with the International Vaccine Institute (IVI) (South Korea) to utilize Seegene's HPV diagnostic reagent for conducting HPV tests in approximately 50,000 people across eight Asian and African countries for up to five years from August.
-
In April 2023, QIAGEN N.V. (Netherlands) launched the QIAstat-Dx syndromic testing solution and SARS-CoV-2 Respiratory Panel in Japan. The SARS-CoV-2 Respiratory Panel detects more than 20 pathogens from a single patient sample.
- In February 2023, F. Hoffmann-La Roche Ltd. (Switzerland) collaborated with Janssen Biotech Inc. (U.S.) to create multiple companion diagnostic technologies, including immunoassays, digital pathology, PCR, next-generation sequencing, and immunohistochemistry.
- In February 2023, Thermo Fisher Scientific, Inc. (U.S.) launched ‘Applied Biosystems TaqPath’ PCR kits for infectious diseases such as genetic analysis (HLA B27), Multi-Drug Resistant Tuberculosis (MTB MDR), Human Immunodeficiency Virus (HIV), M. Tuberculosis complex (MTB), Hepatitis C Virus (HCV), and Hepatitis B Virus (HBV). The kits also have received licensing rights from the Central Drugs Standard Control Organization (CDSCO) and are manufactured in India in association with Mylab Discovery Solutions (India).
Multiplex Assays Market Research Summary:
|
Particulars |
Details |
|
Number of Pages |
262 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
8.9% |
|
Estimated Market Size (Value) |
$6.80 billion by 2031 |
|
Segments Covered |
By Type
By Product
By Technology
By Application
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa |
|
Key Companies |
The key players operating in the multiplex assays market are Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Seegene, Inc. (South Korea), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Illumina, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Quanterix Corporation (U.S.), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany). |
Key questions answered in the multiplex assays market report:
The multiplex assays market covers the study of various segments, including type, product, technology, application, and end-user at regional and country levels. The report also provides insights on factors impacting market growth, regulatory analysis, pricing analysis, and Porter’s five forces analysis.
The multiplex assays market is projected to reach $6.80 billion by 2031 at a CAGR of 8.9% during the forecast period.
Among the types, the protein multiplex assays segment is estimated to hold a major market share in 2024. Increasing use of protein multiplex assays for the simultaneous detection of the protein analytes in the sample. Protein multiplex assays are used to simultaneously detect chemokine, growth factors, cytokines, and others, which are the major factors for understanding the disease mechanism.
The growth of this market is attributed to several factors: the advantages of multiplex assays over singleplex assays, the growing use of multiplexing in companion diagnostics, the increasing prevalence of chronic and infectious diseases, and rising awareness about the importance of early disease diagnosis. The growing need for high-throughput and automated laboratory systems and the increasing focus on personalized medicine are expected to generate growth opportunities for the players operating in this market.
The key players operating in the multiplex assays market are Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Seegene, Inc. (South Korea), Qiagen N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Illumina, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Quanterix Corporation (U.S.), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany).
The emerging countries in the Asian-Pacific are projected to offer significant growth opportunities for the vendors in this market due to the advancing healthcare infrastructure, increasing research laboratories, and rising research funding in the healthcare & pharmaceutical industry.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.1.1. Advantages of Multiplex Assays over Singleplex Assays Leading to their Increased Adoption
4.2.1.2. Growing Use of Multiplexing in Companion Diagnostics Driving the Demand for Multiplex Assays
4.2.1.3. High Costs of Multiplex Assay Equipment Hampering Adoption Among End Users
4.2.1.4. Increasing Focus on Personalized Medicine Boosting the Utilization of Multiplex Assays
4.2.1.5. Shortage of Skilled Professionals and the Risk of Cross-reactivity Limiting the Adoption of Multiplex Assays
4.2.2. Factor Analysis
4.3. Technology Trends
4.3.1. Technological Advancements in Multiplex PCR Technology
4.3.2. Integration of Artificial Intelligence and Machine Learning into Multiplex Assay Systems
4.3.3. Development of Smartphone-based Diagnostic Testing Platforms
4.4. Regulatory Analysis
4.4.1. North America
4.4.1.1. U.S.
4.4.1.2. Canada
4.4.2. Europe
4.4.3. Asia-Pacific
4.4.3.1. China
4.4.3.2. India
4.4.3.3. Japan
4.4.3.4. South Korea
4.4.4. Latin America
4.4.5. Middle East & Africa
4.5. Pricing Analysis
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Suppliers
4.6.2. Bargaining Power of Buyers
4.6.3. Threat of Substitutes
4.6.4. Threat of New Entrants
4.6.5. Degree of Competition
5. Multiplex Assays Market Assessment—by Type
5.1. Overview
5.2. Protein Multiplex Assays
5.2.1. Bead-based Assays
5.2.2. Planar Assays
5.3. Nucleic Acid Multiplex Assays
5.4. Cell-based Multiplex Assays
6. Multiplex Assays Market Assessment—by Product
6.1. Overview
6.2. Consumables
6.3. Instruments
6.4. Software & Services
7. Multiplex Assays Market Assessment—by Technology
7.1. Overview
7.2. Flow Cytometry
7.3. Multiplex Immunoassay
7.4. Multiplex Real-time PCR
7.5. Sequencing
7.6. Other Technologies
8. Multiplex Assays Market Assessment—by Application
8.1. Overview
8.2. Research & Development
8.3. Clinical Diagnosis
8.3.1. Infectious Diseases
8.3.2. Oncology
8.3.3. Cardiovascular Diseases
8.3.4. Autoimmune Diseases
8.3.5. Other Diseases
9. Multiplex Assays Market Assessment—by End User
9.1. Overview
9.2. Pharmaceutical & Biotechnology Companies
9.3. Diagnostic Laboratories
9.4. Hospitals
9.5. Other End Users
10. Multiplex Assays Market Assessment—by Geography
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. U.K.
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Middle East & Africa
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
12. Company Profiles
12.1. Seegene, Inc.
12.2. F. Hoffmann-La Roche Ltd.
12.3. Thermo Fisher Scientific, Inc.
12.4. Illumina, Inc.
12.5. QIAGEN N.V.
12.6. Becton, Dickinson and Company
12.7. Bio-Rad Laboratories, Inc.
12.8. DiaSorin S.p.A.
12.9. PerkinElmer, Inc.
12.10. Agilent Technologies, Inc.
12.11. Abbott Laboratories
12.12. Siemens Healthineers AG
12.13. Merck KGaA
12.14. Quanterix Corporation
(Note: SWOT analysis is provided for the top 5 companies)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Estimated Number of New Cancer Cases, by Type (2022 Vs. 2030)
Table 2 Some of The Emergency Use Authorizations (EUA) Granted for Multiplex Assays During the Covid-19 Pandemic
Table 3 Medical Devices Regulatory Authorities in the Rest of APAC Countries
Table 4 IVD Regulatory Systems, by Country
Table 5 Average Selling Price of Multiplex Assays Products (Price/ USD)
Table 6 Thermo Fisher Scientific, Inc. (U.S.): Multiplex Assays Prices
Table 7 R&D Systems (U.S.): Multiplex Assays Prices
Table 8 Quanterix Corporation (U.S.): Multiplex Assays Prices
Table 9 Global Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 10 Global Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 11 Global Protein Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 12 Global Bead-based Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Global Planar Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 14 Global Nucleic Acid Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Cell-Based Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 17 Key Companies Offering Consumables for Multiplex Assays
Table 18 Global Multiplex Assay Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 19 Global Multiplex Assay Instruments Market, by Country/Region, 2022–2031 (USD Million)
Table 20 Key Companies Offering Software
Table 21 Global Multiplex Assay Software & Services Market, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 23 Global Multiplex Assays Market for Flow Cytometry, by Country/Region, 2022–2031 (USD Million)
Table 24 Global Multiplex Assays Market for Multiplex Immunoassay, by Country/Region, 2022–2031 (USD Million)
Table 25 Global Multiplex Assays Market for Multiplex Real-Time PCR, by Country/Region, 2022–2031 (USD Million)
Table 26 Global Multiplex Assays Market for Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 27 Global Multiplex Assays Market for Other Technologies, by Country/Region, 2022–2031 (USD Million)
Table 28 Global Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 29 Global Multiplex Assays Market for Research & Development, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 31 Global Multiplex Assays Market for Clinical Diagnosis, by Country/Region, 2022–2031 (USD Million)
Table 32 COVID-19 Testing Kits
Table 33 Global Multiplex Assays Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 34 Global Multiplex Assays Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 35 Global Multiplex Assays Market for Cardiovascular Diseases, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Multiplex Assays Market For Autoimmune Diseases, by Country/Region, 2022–2031 (USD Million)
Table 37 Global Multiplex Assays Market for Other Diseases, by Country/Region, 2022–2031 (USD Million)
Table 38 Global Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 39 Global Multiplex Assays Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 40 Global Multiplex Assays Market for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 41 Global Multiplex Assays Market for Hospitals, by Country/Region, 2022–2031 (USD Million)
Table 42 Global Multiplex Assays Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 43 Global Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 44 North America: Multiplex Assays Market, by Country, 2022–2031 (USD Million)
Table 45 North America: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 46 North America: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 47 North America: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 48 North America: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 49 North America: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 50 North America: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 51 North America: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 52 U.S.: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 53 U.S.: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 54 U.S.: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 55 U.S.: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 56 U.S.: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 57 U.S.: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 58 U.S.: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 59 Canada: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 60 Canada: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 61 Canada: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 62 Canada: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 63 Canada: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 64 Canada: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 65 Canada: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 66 Europe: Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 67 Europe: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 68 Europe: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 69 Europe: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 70 Europe: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 71 Europe: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 72 Europe: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 73 Europe: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 74 Germany: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 75 Germany: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 76 Germany: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 77 Germany: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 78 Germany: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 79 Germany: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 80 Germany: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 81 France: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 82 France: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 83 France: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 84 France: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 85 France: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 86 France: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 87 France: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 88 U.K.: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 89 U.K.: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 90 U.K.: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 91 U.K.: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 92 U.K.: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 93 U.K.: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 94 U.K.: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 95 Italy: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 96 Italy: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 97 Italy: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 98 Italy: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 99 Italy: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 100 Italy: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 101 Italy: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 102 Spain: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 103 Spain: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 104 Spain: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 105 Spain: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 106 Spain: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 107 Spain: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 108 Spain: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 109 COVID-19 Cases in European Countries
Table 110 Rest of Europe: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 111 Rest of Europe: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 112 Rest of Europe: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 113 Rest of Europe: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 114 Rest of Europe: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 115 Rest of Europe: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 116 Rest of Europe: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 117 Asia-Pacific: Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 118 Asia-Pacific: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 119 Asia-Pacific: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 120 Asia-Pacific: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 121 Asia-Pacific: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 122 Asia-Pacific: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 123 Asia-Pacific: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 124 Asia-Pacific: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 125 China: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 126 China: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 127 China: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 128 China: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 129 China: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 130 China: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 131 China: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 132 Japan: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 133 Japan: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 134 Japan: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 135 Japan: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 136 Japan: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 137 Japan: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 138 Japan: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 139 India: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 140 India: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 141 India: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 142 India: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 143 India: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 144 India: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 145 India: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 146 Rest of Asia-Pacific: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 147 Rest of Asia-Pacific: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 148 Rest of Asia-Pacific: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 149 Rest of Asia-Pacific: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 150 Rest of Asia-Pacific: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 151 Rest of Asia-Pacific: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 152 Rest of Asia-Pacific: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 153 Latin America: Multiplex Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 154 Latin America: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 155 Latin America: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 156 Latin America: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 157 Latin America: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 158 Latin America: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 159 Latin America: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 160 Latin America: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 161 Brazil: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 162 Brazil: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 163 Brazil: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 164 Brazil: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 165 Brazil: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 166 Brazil: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 167 Brazil: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 168 Mexico: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 169 Mexico: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 170 Mexico: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 171 Mexico: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 172 Mexico: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 173 Mexico: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 ( USD Million)
Table 174 Mexico: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 175 Rest of Latin America: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 176 Rest of Latin America: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 177 Rest of Latin America: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 178 Rest of Latin America: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 179 Rest of Latin America: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 180 Rest of Latin America: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 181 Rest of Latin America: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 182 Middle East & Africa: Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 183 Middle East & Africa: Protein Multiplex Assays Market, by Type, 2022–2031 (USD Million)
Table 184 Middle East & Africa: Multiplex Assays Market, by Product, 2022–2031 (USD Million)
Table 185 Middle East & Africa: Multiplex Assays Market, by Technology, 2022–2031 (USD Million)
Table 186 Middle East & Africa: Multiplex Assays Market, by Application, 2022–2031 (USD Million)
Table 187 Middle East & Africa: Multiplex Assays Market for Clinical Diagnosis, by Type, 2022–2031 (USD Million)
Table 188 Middle East & Africa: Multiplex Assays Market, by End User, 2022–2031 (USD Million)
Table 189 Recent Developments, by Company, 2021–2024
List of Figures
Figure 1 Market Ecosystem
Figure 2 Key Stakeholders
Figure 3 Research Process
Figure 4 Secondary Sources Referenced for This Study
Figure 5 Primary Research Techniques
Figure 6 Key Executives Interviewed
Figure 7 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 8 Market Sizing and Growth Forecast Approach
Figure 9 Global Multiplex Assays Market, By Type, 2024 Vs. 2031 (USD Million)
Figure 10 Global Multiplex Assays Market, By Product, 2024 Vs. 2031 (USD Million)
Figure 11 Global Multiplex Assays Market, By Technology, 2024 Vs. 2031 (USD Million)
Figure 12 Global Multiplex Assays Market, By Application, 2024 Vs. 2031 (USD Million)
Figure 13 Global Multiplex Assays Market, By End User, 2024 Vs. 2031 (USD Million)
Figure 14 Global Multiplex Assays Market, By Geography
Figure 15 Impact Analysis of Market Dynamics
Figure 16 Pharmaceutical R&D Expenditures in The U.S., Europe, And China, 2010 Vs. 2019 Vs. 2021 (USD Million)
Figure 17 Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
Figure 18 EU Regulatory Pathway – IVDR 2017/746
Figure 19 Porter’s Five Forces Analysis
Figure 20 Global Multiplex Assays Market, By Type, 2024 Vs. 2031 (USD Million)
Figure 21 Global Multiplex Assays Market, By Product, 2024 Vs. 2031 (USD Million)
Figure 22 Global Multiplex Assays Market, By Technology, 2024 Vs. 2031 (USD Million)
Figure 23 Global Multiplex Assays Market, By Application, 2024 Vs. 2031 (USD Million)
Figure 24 U.S.: New Molecular Entity (NME) Approvals (2011-2023)
Figure 25 Estimated Number of New Cancer Cases (In Million)
Figure 26 Global Multiplex Assays Market, By End User, 2024 Vs. 2031 (USD Million)
Figure 27 Global Pharmaceutical R&D Spending, 2012–2026 (USD Billion)
Figure 28 Global Multiplex Assays Market, By Region, 2024 Vs. 2031 (USD Million)
Figure 29 North America: Number of People Aged 65 Years and Above, 2015–2022 (In Million)
Figure 30 North America: Multiplex Assays Market Snapshot
Figure 31 U.S.: Pharmaceutical R&D Expenditure, 2014–2021 (USD Billion)
Figure 32 Europe: Pharmaceutical Industry R&D Expenditure, 2000–2021 (USD Million)
Figure 33 Europe: Multiplex Assays Market Snapshot
Figure 34 U.K: Estimated Number of Cancer Cases, 2022–2030 (In Million)
Figure 35 U.K.: Number of People Diagnosed with Sexually Transmitted Infections, 2018–2020 (In Thousand)
Figure 36 Pharmaceutical R&D Expenditure, by Country, 2020 (USD Million)
Figure 37 Asia-Pacific: Multiplex Assays Market Snapshot
Figure 38 Latin America: Multiplex Assays Market Snapshot
Figure 39 Key Growth Strategies Adopted by Leading Players, 2021–2024
Figure 40 Multiplex Assays Market: Competitive Benchmarking (Based on Products)
Figure 41 Multiplex Assays Market: Competitive Benchmarking (Based on Geography)
Figure 42 Competitive Dashboard: Multiplex Assays Market
Figure 43 Seegene, Inc.: Financial Overview (2023)
Figure 44 F. Hoffmann-La Roche Ltd: Financial Overview (2023)
Figure 45 Thermo Fisher Scientific, Inc.: Financial Overview (2023)
Figure 46 Illumina, Inc.: Financial Overview (2023)
Figure 47 Qiagen N.V.: Financial Overview (2023)
Figure 48 Becton, Dickinson and Company: Financial Overview (2023)
Figure 49 Bio-Rad Laboratories: Financial Overview (2023)
Figure 50 DiaSorin S.p.A.: Financial Overview (2023)
Figure 51 PerkinElmer, Inc.: Financial Overview (2023)
Figure 52 Agilent Technologies, Inc.: Financial Overview (2023)
Figure 53 Abbott Laboratories: Financial Overview (2023)
Figure 54 Siemens Healthineers Ag: Financial Overview (2023)
Figure 55 Merck KGaA.: Financial Overview (2023)
Figure 56 Quanterix Corporation: Financial Overview (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
IVD Assay Development Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Oct-2024
Protein Assays Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Aug-2024
Lateral Flow Assays Market - Global Opportunity Analysis And Industry Forecast (2020-2027)
Published Date: Jun-2021
High Throughput Screening Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Mar-2024
